Multiple factors play a role in determining the outcome of schizophrenia. However, the role of these factors is poorly understood, and research findings so far have been inconclusive and sometimes contradictory. Various demographic and baseline clinical factors have been reported to be associated with treatment outcome. Also, early symptom reduction after initiation of antipsychotic therapy is closely related to later treatment response.
However, associations as such do not necessarily imply predictive value, and none of these factors can be regarded as clinically useful in predicting treatment outcome. This article discusses selected aspects of treatment outcome and its prediction in schizophrenia, focusing particularly on early treatment response, ethnicity, neurological soft signs, and the predictive value of a discriminant functional analysis model utilising a combination of putative predictors. Such a model holds promise, and it is to be hoped that future refinements will lead to a clinically useful model for predicting outcome. While an association between early treatment response and treatment outcome has long been recognised, [16] [17] [18] [19] [20] [21] [22] [23] it was not until recently that this topic has been studied in any detail. A meta-analysis 24 respectively. However, 25% did not respond until after the 4th week, and 11% after the 8th week. It would therefore appear that, with first exposure to antipsychotic medication, while more patients respond within the first 2 weeks, the time to response varies widely and a subset of patients take much longer. 26 These apparent differences in treatment response between first-and multi-episode patients have important implications for future practice guidelines when suggesting the duration of a treatment trial of antipsychotic medication. The clinical course of schizophrenia varies across cultures, with the outcome in developing countries generally being regarded as more favourable, 30 although the evidence is not conclusive. 31 Various explanations for this phenomenon have been proposed. For example, certain personal dynamics within the patient's family, particularly retention of the extended family, have been suggested as protective factors. 32 Another possibility is that the illness expresses itself differently in certain ethnic groups. However, this is unlikely as studies have generally failed to show significant cross-cultural differences in core psychotic features. On the contrary, studies of the symptom structure of schizophrenia report them to be remarkably similar across cultures. 33 Most published studies reporting ethnic differences in antipsychotic treatment have been retrospective chart reviews. While these studies have consistently reported racial disparities in the dose, route of delivery (oral versus depot) and class of antipsychotic medication (conventional versus new-generation), reasons for these discrepancies are essentially speculative. African Americans are more likely than Caucasians to receive higher antipsychotic doses; 34 they are also more likely to be prescribed long-acting depot formulations of antipsychotics, 35 and are less likely than whites to receive new-generation antipsychotics. 36 On the other hand, Asian Americans are more likely to receive lower doses of antipsychotics than Caucasians, 37 and are reported to have higher plasma concentrations of antipsychotics. 38 While the finding that African Americans are more likely to be prescribed higher doses and to receive depot antipsychotics and conventional rather than second-generation antipsychotics suggests a greater degree of refractoriness to treatment, the opposite may in fact be the case. We conducted a study in which we investigated the racial differences in 6-week outcome in randomised, controlled trials among the three most prevalent racial groups in South Africa (blacks, whites and mixed descent). 39 We found that whites had the poorest response to acute antipsychotic treatment, while the mixeddescent and black patients responded significantly better (p = 0.0001 and p = 0.005, respectively). But, we also found that baseline psychopathology scores for the black and mixed-descent groups were significantly higher than those for whites, possibly as a result of delayed help-seeking. 39 Racial bias in health services remains a significant problem in many countries, including South Africa 40 and the USA. 41 The new-generation antipsychotics have substantially changed the way we treat patients with schizophrenia. But because of their much greater acquisition costs, patients in lower-income countries, particularly in Africa, Latin America, Asia and the Pacific, are being denied access to these treatments. 42 This is of concern, and raises important human rights issues as the gap between the levels of psychiatric care in developed and developing countries continues to widen. 43 Considering the evidence for superior efficacy and acceptability of the new-generation antipsychotics compared with their older counterparts, poverty becomes a risk factor for poorer outcome in schizophrenia.
Ethnicity and outcome

Neurological 'soft' signs and treatment outcome
Subtle neurological abnormalities are more common in patients with schizophrenia than in healthy controls [44] [45] [46] [47] [48] [49] [50] or patients with other psychotic disorders, 50 and they are generally stable over time. [51] [52] These so-called neurological 'soft' signs (NSSs) are present at an early stage in the illness 49, 50, [53] [54] [55] and are considered to be nonspecific markers of neurodevelopmental abnormality. 56 Alternatively, it has been proposed that NSSs are secondary to psychiatric symptoms such as impaired attention, or even to the sideeffects of antipsychotic medication. 57 NSSs have been associated with poor treatment outcome, 12 although their predictive power has not been formally assessed. In a study conducted at our centre in a sample of 66 largely medicationnaïve first-episode subjects, 58 while the NSS total scores did not change significantly over time, some tests were related to longer duration of untreated psychosis, and showed a tendency to improve as psychiatric symptoms resolved. Also, tests involving motor sequencing tasks were highly significant predictors of the later development of tardive dyskinesia. 58 This finding is of potential importance in outcome prediction,
as an association has been suggested between tardive dyskinesia and refractoriness in schizophrenia. 59
Assessing the clinical value of predictors of outcome
Since the introduction of the first effective pharmacological treatments for schizophrenia, researchers have attempted to identify factors that could predict the outcome of treatment. 60 There would be considerable benefits if it were possible to predict treatment outcome reliably. response (e.g. 20% improvement in psychopathology scores from baseline), 61 relapse rates 62 or remission. 63 Unfortunately, once again different criteria have been applied to define these measures.
In the assessment of outcome in schizophrenia our focus has changed over the years. This is to be expected as advances in treatment and management have emerged and a greater awareness of optimising outcome has developed. Thus, in the pre-antipsychotic era treatment was aimed largely months. While these proposed criteria may not be ideal, and have yet to be tested for their external validity, they represent a point of departure from which later refinements can be made. It is likely that the usefulness of these criteria will be assed in various research settings.
With this in mind, we applied these criteria to a sample of 57 subjects with first-episode psychosis who participated in a prospective study over 24 months, and evaluated various potential predictors of outcome. 65 The primary aim of our study was to identify any baseline and early treatment variables that could be useful to clinicians in predicting remission and non-remission. We evaluated various demographic, baseline clinical and early treatment response variables for their power to predict remission or non-remission by means of a discriminant analysis model. We found that while 70% of the sample managed to meet the cross-sectional remission criteria for symptom reduction at some point in the study, only 40% managed to achieve the full criteria when the 6month duration was applied. Also, only 33% were able to maintain their remission status to completion of the trial. The discriminant analysis model identified 4 variables that could correctly predict 80% of remitters and 82% of non-remitters.
These predictor variables were: early clinical response (6 weeks), NSSs, DUP and the presence of depressive signs at baseline. Based on these and other findings, the following items may be useful in predicting patients who are likely to respond poorly to standard antipsychotic therapy: less than 20% improvement from baseline in PANSS total scores at 6 weeks, DUP > 1 year, presence of NSSs, and absence of depressive symptoms at baseline.
Future research is likely to refine the predictive capacity of demographic and clinical variables. However, early identification of poor responders to standard antipsychotic therapy alone is not sufficient. At the same time, new developments in the treatment of refractory patients will hopefully offer these patients other options in addition to the use of clozapine.
